Stocks That Hit 52-Week Lows On Friday
Before 10 am on Friday, 110 companies set new 52-week lows.
SVB Leerink Maintains Outperform on Silk Road Medical, Lowers Price Target to $66
SVB Leerink analyst Danielle Antalffy maintains Silk Road Medical (NASDAQ:SILK) with a Outperform and lowers the price target from $75 to $66.
Silk Road Medical Q3 EPS $(0.40) Misses $(0.30) Estimate, Sales $24.70M Miss $26.23M Estimate
Silk Road Medical (NASDAQ:SILK) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.30) by 33.33 percent. This is a 29.03 percent decrease over losses of $(0.31) per share
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
Earnings Scheduled For July 29, 2021
Companies Reporting Before The Bell
• Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter.
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 14)
First Ever Standard Surgical Risk Patient TCAR Data to be Presented at the Society for Vascular Surgery 2021 Vascular Annual Meeting
Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that key data regarding standard risk patients undergoing treatment for